Cargando…

Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center

Introduction: TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We have reported a retrospective analysis of newly diagnosed Chinese GBM patients who received TTFields/TMZ treatment and TMZ treatment from A...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chunjui, Xu, Hao, Song, Kun, Zhang, Yi, Zhang, Junyan, Wang, Yang, Sheng, Xiaofang, Chen, Lingchao, Qin, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570572/
https://www.ncbi.nlm.nih.gov/pubmed/36233722
http://dx.doi.org/10.3390/jcm11195855
_version_ 1784810144138264576
author Chen, Chunjui
Xu, Hao
Song, Kun
Zhang, Yi
Zhang, Junyan
Wang, Yang
Sheng, Xiaofang
Chen, Lingchao
Qin, Zhiyong
author_facet Chen, Chunjui
Xu, Hao
Song, Kun
Zhang, Yi
Zhang, Junyan
Wang, Yang
Sheng, Xiaofang
Chen, Lingchao
Qin, Zhiyong
author_sort Chen, Chunjui
collection PubMed
description Introduction: TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We have reported a retrospective analysis of newly diagnosed Chinese GBM patients who received TTFields/TMZ treatment and TMZ treatment from August 2018 to May 2021 in Huashan hospital in Shanghai. Methods: Overall survival (OS) and progression-free survival (PFS) curves were constructed using the Kaplan–Meier method. A Cox proportional hazards regression model, propensity score matched data, and inverse probability of treatment weighting (IPTW) based on propensity score were used to assess the effect of TTFields and account for confounding factors. Results: In the preliminary analysis, the median PFS in TTFields/TMZ group was 16 months (95% CI, 9.6–24.6) versus 11 months (95% CI, 9–12) in TMZ group (p < 0.05). Median overall survival was 21.8 months (95% CI, 17.4-NA) with TTFields/TMZ versus 15 months (HR = 0.43; 95% CI, 13–18) with TMZ alone. The multivariate analysis identified surgery type, STUPP scheme, IDH status, and TTFields use as favorable prognostic factors. After PSM adjustment, the variate among the groups was similar, except that the methylation rate of MGMT promoter remained high in the TMZ group (12 v 32 months; p = 0.011). Upon IPTW Survival analysis, TTFields was associated with a significantly lower risk of death (HR = 0.19 in OS; 95% CI, 0.09–0.41) and progression (HR = 0.35; 95% CI 0.14–0.9) compared with TMZ group. Conclusion: In the final analysis of our single-center Chinese patients with glioblastoma, adding TTFields to temozolomide chemotherapy resulted in statistically significant improvement in PFS and OS.
format Online
Article
Text
id pubmed-9570572
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95705722022-10-17 Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center Chen, Chunjui Xu, Hao Song, Kun Zhang, Yi Zhang, Junyan Wang, Yang Sheng, Xiaofang Chen, Lingchao Qin, Zhiyong J Clin Med Article Introduction: TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We have reported a retrospective analysis of newly diagnosed Chinese GBM patients who received TTFields/TMZ treatment and TMZ treatment from August 2018 to May 2021 in Huashan hospital in Shanghai. Methods: Overall survival (OS) and progression-free survival (PFS) curves were constructed using the Kaplan–Meier method. A Cox proportional hazards regression model, propensity score matched data, and inverse probability of treatment weighting (IPTW) based on propensity score were used to assess the effect of TTFields and account for confounding factors. Results: In the preliminary analysis, the median PFS in TTFields/TMZ group was 16 months (95% CI, 9.6–24.6) versus 11 months (95% CI, 9–12) in TMZ group (p < 0.05). Median overall survival was 21.8 months (95% CI, 17.4-NA) with TTFields/TMZ versus 15 months (HR = 0.43; 95% CI, 13–18) with TMZ alone. The multivariate analysis identified surgery type, STUPP scheme, IDH status, and TTFields use as favorable prognostic factors. After PSM adjustment, the variate among the groups was similar, except that the methylation rate of MGMT promoter remained high in the TMZ group (12 v 32 months; p = 0.011). Upon IPTW Survival analysis, TTFields was associated with a significantly lower risk of death (HR = 0.19 in OS; 95% CI, 0.09–0.41) and progression (HR = 0.35; 95% CI 0.14–0.9) compared with TMZ group. Conclusion: In the final analysis of our single-center Chinese patients with glioblastoma, adding TTFields to temozolomide chemotherapy resulted in statistically significant improvement in PFS and OS. MDPI 2022-10-03 /pmc/articles/PMC9570572/ /pubmed/36233722 http://dx.doi.org/10.3390/jcm11195855 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Chunjui
Xu, Hao
Song, Kun
Zhang, Yi
Zhang, Junyan
Wang, Yang
Sheng, Xiaofang
Chen, Lingchao
Qin, Zhiyong
Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
title Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
title_full Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
title_fullStr Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
title_full_unstemmed Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
title_short Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
title_sort tumor treating fields combine with temozolomide for newly diagnosed glioblastoma: a retrospective analysis of chinese patients in a single center
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570572/
https://www.ncbi.nlm.nih.gov/pubmed/36233722
http://dx.doi.org/10.3390/jcm11195855
work_keys_str_mv AT chenchunjui tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter
AT xuhao tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter
AT songkun tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter
AT zhangyi tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter
AT zhangjunyan tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter
AT wangyang tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter
AT shengxiaofang tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter
AT chenlingchao tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter
AT qinzhiyong tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter